The Shortage Is Over: Moving a Patient Off a Compounded GLP-1 She Can Actually Afford
A patient on compounded tirzepatide, started during the real national shortage, now faces a closing legal and regulatory pathway — and a cost gap that made the compounded product her only affordable option in the first place.
Angela P., a 47-year-old school bus driver, started compounded tirzepatide eighteen months ago through a telehealth service, back when the branded product was genuinely difficult to find at any pharmacy within an hour of her house and her insurance, at the time, covered neither version. She's lost 34 pounds since, brought her blood pressure down from a consistent 142/90 to 124/80, and has been paying roughly $300 a month out of pocket for a product she assumed, reasonably, was simply a cheaper version of the same drug her cousin gets through his own prescription. She'd never heard the word 'compounded' used in any context that suggested it might mean something pharmacologically distinct from what he was taking.
The eighteen points her systolic pressure has come down is the part of her result she has never once cited as a reason to continue, and the part least likely to survive an interruption she doesn't choose. The regulatory ground under her assumption, meanwhile, has shifted substantially since she started. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, closing the shortage-based legal exception that had let compounding pharmacies produce large-scale copies of both drugs; more recently, in April 2026, the agency proposed permanently excluding tirzepatide, semaglutide, and liraglutide from the list of substances outsourcing facilities may compound from at all. What remains is a narrower exception for individual, clinically-justified compounding, which affordability alone does not satisfy under the FDA's own stated position — a gap between what Angela has been taking and what she's now actually allowed to keep taking that has nothing to do with whether the drug has been working for her.
In clinic, a closed pathway and an open cost problem
I'd move her off the compounded product now rather than wait for the FDA's proposed rule to finalize. Both the tirzepatide and semaglutide shortages were formally declared resolved by the FDA in late 2024 and early 2025, closing the shortage-based legal pathway compounders had been operating under; the 503A patient-specific exception that remains requires a documented clinical reason a commercial product can't meet, and 'it's less expensive' doesn't meet that bar under the FDA's own stated position.
I don't disagree about the legal picture, but I want to name the compounded product's real, specific risk before we frame this purely as a compliance question. Compounded formulations often use salt forms like semaglutide sodium rather than the exact molecule studied in the approved product's trials, and some products have been found to include unproven additives — B12, other vitamins — that were never part of what was actually tested. This isn't a generic-versus-brand question; the compounded product may not be pharmacologically identical to what she thinks she's been taking.
Cost is a real barrier and I don't want to wave it away, but it's a separate problem from whether the product itself is safe and consistent, and conflating the two risks under-selling how different those two arguments actually are.
That's a fair addition, and it strengthens rather than replaces the compliance argument. I'd help her explore manufacturer savings programs and patient-assistance options for the branded product before assuming cost makes this impossible — several exist specifically because this exact affordability gap is well recognized, and it's worth exhausting those before treating the compounded product as her only realistic option.
Agreed: begin the transition to branded tirzepatide and apply for manufacturer savings-program support before Angela's next fill is due, rather than leave her without a bridge between the two products. Both physicians treated the affordability barrier as a real clinical problem to be solved, not a footnote to the regulatory recommendation.
Not agreed: what to do if the savings program doesn't close the cost gap enough for her to sustain treatment. The internal medicine physician would still recommend stopping the compounded product regardless, given the closing legal pathway; the pharmacologist was less certain that outcome was acceptable if it meant Angela simply going without therapy, and raised revisiting a lower-intensity, more affordable alternative (an oral agent, or a lower-potency GLP-1) rather than no treatment at all. That specific fallback was left for the next visit, pending the savings-program result.